It has been recently reported that EZH2 inhibition increases cell apoptosis and reduces cell proliferation in glioma (Wang et al., 2019), and it also potentially prevents macrophage-dependent disease development (Neele and de Winther, 2018). Here, EZH2 is linked to central nervous system cancer.